181 related articles for article (PubMed ID: 16641912)
1. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival.
Parker C; Muston D; Melia J; Moss S; Dearnaley D
Br J Cancer; 2006 May; 94(10):1361-8. PubMed ID: 16641912
[TBL] [Abstract][Full Text] [Related]
2. Treatment options for localized prostate cancer: quality-adjusted life years and the effects of lead-time.
Bhatnagar V; Stewart ST; Bonney WW; Kaplan RM
Urology; 2004 Jan; 63(1):103-9. PubMed ID: 14751359
[TBL] [Abstract][Full Text] [Related]
3. Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy.
Eggener SE; Roehl KA; Smith ND; Antenor JA; Han M; Catalona WJ
J Urol; 2005 Apr; 173(4):1150-5. PubMed ID: 15758725
[TBL] [Abstract][Full Text] [Related]
4. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.
Khatami A; Hugosson J; Wang W; Damber JE
Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633
[TBL] [Abstract][Full Text] [Related]
5. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
6. Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.
Loeb S; Zhu X; Schroder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1678-83. PubMed ID: 22998182
[TBL] [Abstract][Full Text] [Related]
7. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.
D'Amico AV; Chen MH; Roehl KA; Catalona WJ
N Engl J Med; 2004 Jul; 351(2):125-35. PubMed ID: 15247353
[TBL] [Abstract][Full Text] [Related]
8. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.
Graefen M; Noldus J; Pichlmeier U; Haese A; Hammerer P; Fernandez S; Conrad S; Henke R; Huland E; Huland H
Eur Urol; 1999; 36(1):21-30. PubMed ID: 10364651
[TBL] [Abstract][Full Text] [Related]
9. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.
Freedland SJ; Humphreys EB; Mangold LA; Eisenberger M; Dorey FJ; Walsh PC; Partin AW
JAMA; 2005 Jul; 294(4):433-9. PubMed ID: 16046649
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control.
Pound CR; Partin AW; Epstein JI; Walsh PC
Urol Clin North Am; 1997 May; 24(2):395-406. PubMed ID: 9126237
[TBL] [Abstract][Full Text] [Related]
11. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
Brockman JA; Alanee S; Vickers AJ; Scardino PT; Wood DP; Kibel AS; Lin DW; Bianco FJ; Rabah DM; Klein EA; Ciezki JP; Gao T; Kattan MW; Stephenson AJ
Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
[TBL] [Abstract][Full Text] [Related]
12. Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results.
Roehl KA; Eggener SE; Loeb S; Smith ND; Antenor JA; Catalona WJ
Urol Oncol; 2006; 24(6):465-71. PubMed ID: 17138126
[TBL] [Abstract][Full Text] [Related]
13. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
14. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
15. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
[TBL] [Abstract][Full Text] [Related]
16. Estimating the impact on prostate cancer mortality of incorporating prostate-specific antigen testing into screening.
D'Amico AV; Whittington R; Malkowicz SB; Renshaw AA; Tomaszewski JE; Bentley C; Schultz D; Rocha S; Wein A; Richie JP
Urology; 2001 Sep; 58(3):406-10. PubMed ID: 11549489
[TBL] [Abstract][Full Text] [Related]
17. Impact of surgical margin status on prostate-cancer-specific mortality.
Chalfin HJ; Dinizo M; Trock BJ; Feng Z; Partin AW; Walsh PC; Humphreys E; Han M
BJU Int; 2012 Dec; 110(11):1684-9. PubMed ID: 22788795
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality.
Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
J Urol; 2017 Apr; 197(4):1060-1067. PubMed ID: 27847296
[TBL] [Abstract][Full Text] [Related]
19. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
20. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial.
Godtman RA; Holmberg E; Khatami A; Stranne J; Hugosson J
Eur Urol; 2013 Jan; 63(1):101-7. PubMed ID: 22980443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
